Osteonecrosis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Market is Segmented by Treatment Type (Drugs (Nonsteroidal Anti-Inflammatory Drugs and Cholesterol-Lowering Drugs), and Bone Replacement Devices/Implants) and Geography.

Market Snapshot

osteonecrosis treatment market overview
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.2 %
osteonecrosis treatment market major players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The osteonecrosis treatment market is expected to register a CAGR of 6.2% during the forecast period. Osteonecrosis, also known as avascular necrosis, is the death of bone tissue due to a lack of blood supply, which can lead to tiny breaks in the bone and the bone's eventual collapse. Although the pathophysiology of osteonecrosis or avascular necrosis is not yet well-understood, it is thought to be a multifactorial disease, with patients reporting exposure to one or more risk factors such as alcohol abuse, corticosteroid use, trauma to the hip, chemotherapy, caisson disease, HIV, hemoglobinopathies, and pregnancy. Osteonecrosis occurs when blood flow to a bone is interrupted or reduced, and this can be due to joint or bone trauma, fatty deposits in blood vessels, and certain diseases. Most of the people have no symptoms in the early stages of avascular necrosis. As the condition worsens, the affected joint might hurt and feel the pain, which can be mild or severe and usually develops gradually. Osteonecrosis progression can be halted through core decompression, osteotomy, bone grafting, and other medical treatments.

The rise in the geriatric population increases the incidence of osteonecrosis worldwide, the growing demand for non-invasive treatment, and technological advancements for a better treatment for osteonecrosis are the key driving factors in osteonecrosis treatment market.

Scope of the Report

Osteonecrosis, also known as avascular necrosis, is the death of bone tissue due to a lack of blood supply. The osteonecrosis treatment market is segmented by treatment type and geography.

By Treatment Type
Nonsteroidal Anti-Inflammatory Drugs
Cholesterol-Lowering Drugs
Blood Thinners
Other Drugs
Bone Replacement Devices/Implants
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Drugs Segment is Expected to Hold a Major Market Share in the Osteonecrosis Treatment Market

  • Some of the classes of drugs used to treat osteonecrosis are nonsteroidal anti-inflammatory drugs, cholesterol-lowering drugs, blood thinners, and others.
  • According to the National Organization for Rare Disorder (NORD), in the United States, about 10,000 to 20,000 people develop osteonecrosis every year. Moreover, osteonecrosis affects people between 30 and 50 years of age.
  • Drugs segment holds a significant market share in the osteonecrosis treatment market and is anticipated to show a similar trend over the forecast period due to being highly effective, non-invasive, and fewer side effects than compared to other therapies.
  • Rise in the geriatric population, growing demand for non-invasive treatment and technological advancements for a better treatment for osteonecrosis are the key driving factors in the drugs segment.
osteonecrosis treatment market growth

North America is Expected to Hold a Significant Share in the Market during the Forecast Period

North America expected to hold a major market share in the global osteonecrosis treatment market due to an increase in the geriatric population and growing awareness among people about the diagnosis of the disease in this region. According to the American Population Reference Bureau Report, around 52 million Americans are above 65 years of age in the year 2018, which is projected to reach 95 million by the year 2060. In addition, the 65-and-older age group’s share of the total population will rise from 16 percent to 23 percent. Furthermore, technological advancement and the launch of new treatment options, increasing healthcare spending, and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

osteonecrosis treatment market share

Competitive Landscape

The osteonecrosis treatment market is moderately fragmented competitive and consists of several major players. Some of the leading companies operating in the market include Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Mylan NV, Zimmer Biomet, Merck & Co. Inc., Enzo Biochem Inc., Atnahs, Bone Therapeutics SA, and Vericel Corporation, among others.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Geriatric Population Increases the Incidence of Osteonecrosis Worldwide

      2. 4.2.2 Growing Demand for Non-invasive Treatment

      3. 4.2.3 Technological Advancements for a Better Treatment for Osteonecrosis

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Side Effects Associated with Osteonecrosis Treatment

      2. 4.3.2 Availability of Alternative Methods for Treatment of Osteonecrosis

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Treatment Type

      1. 5.1.1 Drugs

        1. Nonsteroidal Anti-Inflammatory Drugs

        2. Cholesterol-Lowering Drugs

        3. Blood Thinners

        4. Other Drugs

      2. 5.1.2 Bone Replacement Devices/Implants

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Novartis AG

      2. 6.1.2 Pfizer Inc.

      3. 6.1.3 Teva Pharmaceutical Industries Ltd

      4. 6.1.4 Mylan NV

      5. 6.1.5 Zimmer Biomet

      6. 6.1.6 Merck & Co. Inc.

      7. 6.1.7 Enzo Biochem Inc.

      8. 6.1.8 Bone Therapeutics SA

      9. 6.1.9 Vericel Corporation

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Osteonecrosis Treatment Market market is studied from 2018 - 2026.

The Osteonecrosis Treatment Market is growing at a CAGR of 6.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Zimmer Biomet are the major companies operating in Osteonecrosis Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!